Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

NCT03095352 is registered in ClinicalTrials.gov with Laura Huppert, MD, BA as lead sponsor.

NCT NCT03095352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03095352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Lead sponsor
Laura Huppert, MD, BA
Phase
Phase 2
Overall status
Completed
Start date
September 2, 2017
Completion date
November 30, 2024
Enrollment
76 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chest wall disease